Drug Trial Radar · NCT05813925
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
331
Actual
Start
Apr 3, 2023
Primary completion
Jan 17, 2025
Study completion Mar 7, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.
Conditions
- Obesity or Overweight
Interventions
CagrilintideDrug
Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
SemaglutideDrug
Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Placebo SemaglutideDrug
Participants will receive placebo matched to semaglutide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change in Body WeightTime frame: From baseline (week 0) to end of treatment (week 68)
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
Aichi, Japan
The University of Tokyo Hospital, Diabetes and Metabolic
Bunkyo-ku, Tokyo, Japan
Akaicho Clinic
Chiba-shi, Chiba, Japan
Suidoubashi Medical Clinic_Internal Medicine
Chiyoda-ku, Tokyo, Japan
The Institute of Medical Science, Asahi Life Foundation_Internal Medicine
Chuo-ku, Tokyo, Japan
The Institute of Medical Science, Asahi Life Foundation
Chuo-ku, Tokyo, Japan
Okabe Clinic
Chuo-ku, Tokyo, Japan
Kawada Clinic
Gunma, Japan
Naka Kinen Clinic_Internal medicine
Ibaraki, Japan
Naka Kinen Clinic
Ibaraki, Japan
Iwate Medical University Uchimaru Medical Center, Division of Diabetes and Metabolism and Endocrine medicine
Numakunai, Japan
Osaka NISHI-UMEDA Clinic_Internal Medicine
Osaka, Japan
Osaka NISHI-UMEDA Clinic
Osaka, Japan
Shinsapporo Seiryou Hospital, General Clinical Department
Sapporo-shi, Hokkaido, Japan
Shinden Higashi Clinic_Internal medicine
Sendai-shi, Miyagi, Japan
Shinden Higashi Clinic
Sendai-shi, Miyagi, Japan
Tokyo-Eki Center-building Clinic_Internal Medicine
Tokyo, Japan
Fukuwa Clinic_Internal Medicine
Tokyo, Japan
Fukuwa Clinic
Tokyo, Japan
ToCROM Clinic_Internal Medicine
Tokyo, Japan
Minamino Cardiovascular Hospital_Cardiovascular medicine
Tokyo, Japan
Seino Internal Medicine Clinic_Internal medicine
Koriyama-shi, Fukushima, Fukushima, Japan, Japan
Tsuruma Kaneshiro Diabetes Clinic_Internal medicine
Yamato-shi, Kanagawa, Japan
Tsuruma Kaneshiro Diabetes Clinic
Yamato-shi, Kanagawa, Japan
Heiwadai Hospital_Internal Medicine
Miyazaki, Miyazaki, Japan
OCROM Clinic_Internal medicine
Suita-shi, Osaka, Japan
Yao Tokushukai General Hospital_Cardiovascular division
Yao-shi, Osaka, Japan
National Taiwan University Hospital_main
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.